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p53 oncoprotein overexpression correlates with mutagen-induced
chromosome fragility in head and neck cancer patients with multiple
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Smary In this study, we analysed immunocytochemically p53 expression in first primary and second
primary cancers from 25 head and neck cancer patients (HNCPs) with multiple malignancies in comparison
with oncoprotein expression in tumour tissues from 25 historical HNCP controls with single cancer in a
match-paired analysis. Moreover, we investigated bleomycin-induced chromosome fragility in both groups of
HNCPs and in 21 additional healthy controls. Thirty-nine out of 75 tumour specimens analysed (52%) showed
positive p53 immunostaining. Eleven out of 25 (44%) from single cancer patients and 28 out of 50 (56%)
tumours from HNCPs with multiple malignancies were p53 positive. In the group ofmultiple primary cancers,
nine patients (36%) showed positive staining of both first and second primaries, whereas six (24%) had
positive labelling of first primary cancer but not of the subsequent second primary, four (16%) patient showed
p53 expression only in the second primary cancer and six (24%) patients showed no p53 immunoreactivity in
both tumours. Chromosomal analysis demonstrated a higher sensitivity to clastogens of HNCPs with multiple
tumours than of HNCPs with a single cancer (P<0.01), and a significant correlation between chromosome
fragility and p53 overexpression (P<0.01) only in HNCPs with multiple malignancies more than in those with
single head and neck cancer (P = 0.11). Moreover, we found that patients with p53-positive staining of both
first and second primaries showed a statistically significant higher mutagen sensitivity than those with a single
p53 immunoreactive tumour or those in whom both cancers were p53 negative (P<0.01). Our data suggest
that subjects with increased susceptibility to carcinogens after exposure to tobacco or alcohol are at higher risk
for multiple cancers in which one of the most common genetic events is aberrant p53 expression.
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From 10% to 40% of patients with head and neck cancer are
known to have a high risk of developing second primary
neoplasms within a few years following initial diagnosis
(Shikhani et al., 1989; Larson et al., 1990; Haughey et al.,
1992). Factors considered responsible for multiple malignan-
cies in head and neck cancer patients remain incompletely
understood.
In agreement with the 'field cancerisation' theory (Slaugh-
ter et al., 1953), it is likely that in a fraction of patients with
primary cancer of the upper aerodigestive tract prolonged
exposure to carcinogens (alcohol, tobacco smoke) could
generate genetic changes in the epithelial cells of exposed
mucosae, leading to a higher risk of developing second
primary malignancies (Franco et al., 1991; Day et al., 1994).
The population at highest risk of multiple primary tumours
seems to be genetically predisposed, showing an increased
susceptibility to carcinogens, as detected by clastogen-
induced chromosome fragility within peripheral blood lym-
phocytes (Schantz et al., 1990).
Molecular genetics has provided evidence that mutations in
the p53 tumour-suppressor gene are involved in a large
number of primary squamous cell carcinomas of the upper
aerodigestive tract (Nigro et al., 1989; Sakai and Tsuchida,
1990; Maestro et al., 1992; Caamano et al., 1993; Field et al.,
1993). Moreover, the association between cigarette smoking
and p53 gene mutations or overexpression in HNCPs sug-
gests that the p53 tumour-suppressor gene may be a genetic
target of environmental carcinogens (Field et al., 1991, 1992).
Therefore, it is conceivable that independent somatic muta-
tions of the p53 tumour-suppressor gene in different
carcinogen-exposed areas of the upper aerodigestive tract
might be key events in the development of multiple malig-
nancies in genetically predisposed HNCPs.
In order to test our hypothesis, we analysed immunocyto-
chemically the expression of p53 oncogene in tumour tissues
from HNCPs who developed second primary head and neck
cancers in comparison with p53 expression in tumour tissues
from historical HNCP controls without multiple malignan-
cies in a matched-pair analysis. Moreover, we attempted to
ascertain if p53 oncoprotein overexpression correlates with
genetically predisposed high sensitivity to clastogens in
patients with multiple malignancies of the upper aerodiges-
tive tract.
Pate.t and methods
Patients
Between January 1992 and February 1993 at the Institute of
Otolaryngology of the University of Florence, 25 patients
with previously treated squamous cell carcinomas of the head
and neck who experienced second primaries were selected for
our study. The criteria for selection of multiple tumour from
recurrent first primary included: (a) different site of tumour
growth, and only for second lesions growth at the same
primary site; (b) interval between first and second primary
longer than 5 years. To compare the patients who developed
multiple malignancies with a group of patients with similar
prognostic factors who had not developed a second primary
during a period similar to the median follow-up of the first
group (5.7 years, range 0.6-13), we selected 25 patients to
serve as matched controls from a total of 723 patients treated
from 1983 to 1986. Using a computerised search system to
avoid bias, we selected individual controls with the same
factors as the patients with multiple primary cancers without
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reference to the clinical outcome, matching each HNCP with
multiple tumours to his or her control by several parameters
reported in Table I. Tobacco exposure and alcohol consump-
tion were documented retrospectively and recorded in all
individuals. For those individuals who smoked cigarettes,
pack-year history was caculated by multiplying the number
of packs consumed per day by the number of years exposed.
Accordingly, patients with a history of more than 30
pack-years and less than 30 pack-years were considered
heavy and moderate smokers respectively. Because of limited
information only those HNCPs who gave a history of daily
consumption of alcohol-containing beverages were con-
sidered 'alcohol-exposed'. A third study group, composed of
21 healthy subjects (all over 50 years old and moderate to
heavy smokers) were included in the cytogenetic analysis in
order to obtain additional comparative data. The sites offirst
and second primary malignancies are shown in Table H.
Cytogenetic studies
Chromosome analyses were performed on the three study
groups. The test was performed as described previously (Hsu
et al., 1989; Schantz and Hsu, 1989; Spitz et al., 1989), using
as mutagen bleomycin sulphate (Sigma, St Louis, MO, USA)
at the concentration of25Mgml-'. The number ofchromatid
breaks counted in each culture was finally converted into the
number of chromatid breaks per cell (b/c) to facilitate com-
parison, as described elsewhere (Hsu et al., 1989).
Table I Clinil characteristics ofhead and neck cancerpabents with
(group I) and without (group II) multiple malgnancies
Variabk Group I Group HI
Median age (range) (years) 58 (46-70) 60 (47-72)
Sex 22 M and 3 F 22 M and 3 F
Smoking history
Non-smokers 6 6
Moderate smokers 8 9
Heavy smokers 11 10
Alcohol use 10/25 (40'!.) 9/25 (36%)
Site ofprimary
Larynx 12 12
Oral cavity 9 9
Pharynx 4 4
Total 25 25
Stages
I 8 7
II 7 6
III 7 8
IV 3 4
Post-operative radiotherapy 10/25 (40%) 12/25 (48%)
Median follow-up (range) (years) 8.7 (0.6-13) 7.2 (4.8-8.2)
Average period to develop second primary 5.7 (0.6-13)
(ran) (years)
'Refers to firstprimary cancer in group I patients.
Immmocytochemistry
Formalin-fixed paraffin-embedded specimens of the primary
and second primary tumours from each patient were
available for immunocytochemical analysis. Immunocyto-
chemistry was performed using murine monoclonal antibody,
DO-7, against hnumn p53 protein (Dako, Copenhagen, Den-
mark), as reported elsewhere (Shin et al., 1994). The staining
pattern was assessed by one of us (SB) and classified as (-)
for negative or equivocal staining, (+) 1-25% of positive
cells, (+ +) 26-50% ofpositive cells and (+ + +) >50% of
postive cells. Only nuclear staining was regarded as specific
stainig.
Statistical walysis
Statstl comparisons were made with the unpaired Student's
t-test, Fishers's exact test and finally Kruskal-Wallis
analysis. The three following indices and their statstical
parameters (average variance, standard deviation) were used
for chromosomal analysis: %bc, percentage of cells showing
at least one breakage; b/c, breaks per cell (average value for
each subject); mb/c, breaks per cell (maximum value for each
subject). The signifa of differences between the mean
values of the three groups was evaluated using Student's
t-test (double-tailed). The same test was appLied to assess the
significanc of association between cigarette smoking (pack-
years) and p53 expression.
The significance of the statistical association between the
presence of p53 expression and bleomycin-induced chromo-
some fragility was tested by Fisher's exact test. Within each
HNCP group we considered patients to be bleomycin sen-
sitive if they expressed more than 0.2 b/c. In HNCPs with
multiple tumours we considered as positive all patients with
p53-positive immunostaining in at least one tumour specimen
studied.
The analysis ofcorrelations between b/c median values and
p53 immunoreactivity in multiple cancers was performed by
Kruskal-Wallis analysis. All P-values are two-tailed, with
values less than 0.05 considered statistically significant.
Resdts and di rsion
The results of cytogenetic analysis are reported in Tables
III-V. Tbe constitutional karyotype appeared normal in all
subjects in the three groups involved in our study (Giemsa
banding and quinacrine banding). In the untreated cultures
(A,B) none of the subjects belonging to the three groups
expressed an abnormal frequency of spontaneous chromo-
some brekag (range 0.01-0.02) (Figure 1). Culture C,
treated with bleomycin sulphate, was examined for breakage
analysis. There were significant differences in mean values
(%bc, b/c, mb/c) between groups I and II, groups I and IHI,
and finally between groups II and HI (P<0.001). Our data
confirm the orginal reports from Schantz et al. (1990), show-
ing increased bleomycin-induced chromosome fragility in
HNCPs with multiple malignancies as compared with
HNCPs with single cancer in a matched-paired analysis.
However, we found b/c values in our patients lower than
those reported previously by others (Hsu et al., 1989; Schantz
and Hsu, 1989; Spitz et al., 1989).
Seventy-five head and neck squamous cell carcinomas were
investigated for elevated levels of p53 gene expression by
Tab H Second primary site by index tumour in 25 head and neck cancer patients with multiple
malignancies (group I)
Index tunour Ljuag Oesophagus Larynx Oral caity Phrynx Others
Larynx (n= 12) lb 1 2 4 4 -
Oralcavity (n = 9) - 1 2 3a 2 lb
Oropharynx(n = 2) - - - 2 - -
Hypopharynx (n=2) - - - 1 1 -
Total (n = 25) 1 2 4 10 7 1
"InIuded one patient with synchronous tumours. bPatient with more than two tumours.
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immunocytochemistry, of which 50 represented primary and weakly labelled. Moreover, 19 out of 25 (76.0%) patients
second pimary cancers from HNCPs with multiple malig- with multiple malignancies [15 (78.9%) in the first primaryl,
nancies and 25 were cancers from historical controls who did showed positive tumour staining, whereas only 11 out of 25
not have second primary tumours. The overall rate of (44%) primary squamous cell carcinomas from single cancer
positive immunostaining was 52% (39 out of 75); 30.7% (12 controls were positive for p53 oncoprotein immunostaining
out of 39) of these had intense staining, 35.9% (14 out of 39) (Tables III and IV). In the group of HNCPs with multiple
showed moderate staining, while 33.3% (13 out of 39) were cancers, nine patients (36%) showed positive staining of both
Table HI Bleomycin-induced chromosome fragility and p53 expression in head and neck cancer patients with multiple malignancies (group 1).
Colkcted data and related descriptive statistics
Cells with Cells with Total Breaks freaks Smoking
Cells breaks breaks breaks per ceUl per cell history Alcohol
Patient Sex examined (nwnber) (%) (number) (average) (max.) pack/year use
93/147 M 50
93/148 F 50
93/149 M 36
93/150 F 50
93/151 M 25
93/153 M 50
93/154 M 38
93/155 M 39
93/189 M 50
93/190 M 45
93/192 M 40
93/226 M 50
93/230 M 50
93/253 M 50
93/285 M 40
93/391 M 43
93/503 F 35
93/595 M 40
93/799 M 40
93/828 M 30
93/850 M 40
93/877 M 50
93/892 M 45
93/913 M 30
93/915 M 20
Average
Variance
Standard deviation
20
15
9
14
3
3
3
6
18
13
9
13
9
8
2
6
2
12
3
2
10
11
3
2
40.00
30.00
25.00
28.00
20.00
6.00
7.89
15.38
36.00
28.89
22.50
26.00
18.00
16.00
5.00
13.95
14.29
5.00
30.00
10.00
5.00
20.00
24.44
10.00
10.00
19.06
104.03
10.20
50
36
20
28
13
3
5
9
36
19
13
16
20
14
3
12
7
3
15
6
3
14
16
12
5
1.00
0.72
0.56
0.56
0.52
0.06
0.13
0.23
0.72
0.42
0.33
0.32
0.40
0.28
0.08
0.28
0.20
0.08
0.38
0.20
0.08
0.28
0.36
0.40
0.25
0.05
0.23
6
4
5
4
2
2
2
2
3
3
3
2
4
3
2
3
2
2
2
3
2
3
3
3
55
60
30
55
30
55
25
80
15
40
30
25
35
25
40
35
20
90
75
pS3 expression
First cancer Second cancer
++ ++
+_
++ +
+++ ++
+_
+ +_
+_
+++ ~+
++ +
_ +
++++
_ ~++
++
_ ~++
+++
~+++
+ +_
2.96
1.43
1.20
Table IV Bleomycin-induced chromosomefragility andp53expression in head and neck cancerpatients without multiplemalignancies (group II).
Collected data and related descriptive statistics
Cells with Cells with Total
Cells breaks breaks breaks
Patient Sex examined (number) (%) (number)
93/225 M 45 7 15.56 16
93/227 F 50 1 2.00 1
93/228 M 50 7 14.00 16
93/229 M 50 6 12.00 12
93/252 M 38 3 7.86 7
93/254 M 40 6 15.00 8
93/255 M 45 3 6.67 4
93/266 M 50 5 10.00 6
93/269 M 50 11 22.00 13
93/268 M 50 7 14.00 11
93/280 M 30 3 10.00 6
93/281 M 28 2 7.14 4
93/282 M 30 2 6.67 3
93/283 M 35 4 11.43 4
93/284 M 26 3 11.54 8
93/502 F 30 1 3.33 1
93/542 M 50 2 4.00 2
93/586 M 26 2 7.69 2
93/796 M 50 2 4.00 4
93/829 F 50 4 8.00 9
93/798 M 50 7 14.00 16
93/830 M 40 3 7.50 5
93/851 M 35 2 5.71 2
93/914 M 30 1 3.33 1
93/916 M 20 1 5.00 2
Average
Variance
Standard deviation
9.17
22.32
4.72
Breaks Breaks Smoking
per cell per cell history Alkohol p53 expression
(average) (max.) packlyear use in primay cancer
0.36 4 50 + +++
0.02 1 - -
0.32 3 35
- + +
0.24 3 20
- -
0.18 3 30
- ++
0.20 2 55 + +
0.09 2 - + -
0.12 2 -- -
0.26 2 10 + ++
0.22 2 55 - +
0.20 1 25 - -
0.14 2 40 + -
0.10 2 35 - -
0.11 1 - -
0.31 3 +
0.03 1 20 -
0.04 1 45 -
0.08 1 25 -
0.08 2 20 + -
0.18 3 -+
0.32 3 10 - -
0.13 2 55 + +++
0.06 1 25 + -
0.03 1 90 + +++
0.10 2 60 - ++
0.16
0.01
0.10
2.04
0.76
0.87
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Table V Bleomycin-induced chromosome fragility in 21 healthy controls (group III). Collected data and
related descriptive statistics
Cells with Cells with Total Breaks Breaks Smoking
Cells breaks breaks breaks per cell per cell history
Patient Sex examined (number) (%) (nber) (average) (max.) packlyear
93,332 M 20 0 0 0 0.00 0 50
93333 F 25 2 8 2 0.08 1 25
93'378 F 50 4 8 5 0.10 2 35
93 403 F 50 4 8 6 0.12 2 40
93 376 F 40 3 7.5 3 0.08 1 45
93 338 M 12 0 0 0 0.00 0 35
93,'339 F 50 2 4 2 0.04 1 55
93/492 F 50 3 6 5 0.10 2 70
93/493 M 20 0 0 0 0.00 0 90
93/576 M 35 3 8.5 3 0.09 1 40
93/577 F 50 3 6 3 0.06 1 30
931635 M 40 2 5 3 0.08 2 30
93 647 M 50 2 4 2 0.04 1 35
93,668 M 20 0 0 0 0.00 1 55
93 678 M 50 2 4 3 0.06 2 40
93 788 M 50 1 2 1 0.02 1 40
93/811 M 50 1 2 1 0.02 1 30
931820 M 50 0 0 0 0.00 0 55
931/833 M 45 1 2.2 1 0.02 1 75
93/842 M 45 1 2.2 2 0.04 2 60
93/850 M 50 2 4 2 0.04 1 45
Average 3.98 0.05 1.10
Variance 9.40 0.00 0.51
Standard deviation 3.07 1.04 0.71
Figwe 1 Multiple chromatid breaks (arrows) in a lymphocyte
from a primary blood culture treated with bleomycin sulphate
(25 jgml-') in an HNCP with multiple malignancies.
first and second primary cancers, whereas six (24%) had
positive labelling of the first primary cancer but not of the
subsequent second primary, four (16%) patients showed no
p53 overexpression in the initial primary but did have
positive staining in subsequent primary cancers and six
patients (24%) showed no p53 immunoreactivity in both
tumours (Table III). Therefore, in this group the overall
frequencies of p53 overexpression among primary tumours
and second primary cancers were 60% (15 out of 25) and
52% (13 out of 25) respectively.
The analysis of smoking history and of p53 expression in
the 50 patients examined showed that patients with p53-
positive tumours consumed significantly more cigarettes
(mean 50.3 ± 7.5 pack-years) than patients with negative
p53 tumours (mean 17.8 ± 3.2) (P<0.001). In addition, most
of the non-smoking HNCPs (four out of six patients, i.e.
66%) in both groups analysed showed no p53 immunostain-
ing in tumour tissues.
The incidence of 52% of p53-positive tumour specimens
analysed is consistent with the reported frequencies for head
and neck cancer and other solid tumours (Wating et al.,
1992; Anwar et al., 1993; Caamano et al., 1993; Harris and
Hollstein, 1993). Detailed analysis of results in the two
groups of HNCPs analysed shows that the incidence of p53
overexpression in initial primary head and neck cancer is
lower in patients with single tumours than in those with
multiple malignancies (44% vs 60%), and that the p53
tumour-suppressor gene is overexpressed in 52% (13 out of
25) of second primary cancers and in 36% (9 out of 25) of
both primary and second primary cancers from HNCPs with
multiple malignancies. These data further support the
recently reported data (Chung et al., 1993; Nees et al., 1993)
showing discordant p53 gene mutations in primary and cor-
responding second primary cancers ofthe upper aerodigestive
tract, and in uninvolved tumour-distant epithelia of head and
neck cancer patients, suggesting a new possible molecular
basis for the development of multiple tumours.
Correlation between mutagen-induced sensitivity, measured
as number of chromatid breaks per cell (b/c), and p53
tumour expression was statistically significant in all the
HNCPs taken together (P<0.001). Detailed analysis of the
separate groups showed that a significnt correlation between
clastogen-induced chromosome fragility and p53 tumour-
suppressor gene expression exists only in patients with mul-
tiple malignancies (P<0.01), but not in HNCPs with a single
tumour (P = 0.12). Moreover, in the group of patients with
multiple malignancies a statistically significant correlation
exists between chromosome fraglity and p53 immunostain-
ing. Patients with two tumours both p53 positive, had higher
b/c values than those with a single p53-positive cancer or
those with two p53-negative tumours (median b/c value
0.510, 0.306 and 0.178 respectively) (X= 9.32, P<0.02).
These data could suggest a major role for genetic factors in
the development of multiple tumours in HNCPs. In fact, the
sensitivity to bleomycin-induced mutagenesis may reflect a
defective DNA repair capability in the host with a high
susceptibility to the genotoxic effect of environmental car-
cinogens such as tobacco and alcohol (Rarshad et al., 1983;
Hsu et al., 1989; Schantz and Hsu, 1989). Accordingly, the
analysis of p53 oncoprotein expression in our patients
confirms the previously reported correlation between p53
gene muta,tion or overexpression and cigarette smoking in
head and neck and lung cancer patients (Field et al., 1993;
Westra et al., 1993). Thus, it is likely that subjects with
increased susceptibility to carcinogens after exposure to
tobacco or alcohol are at highest risk for multiple cancers in
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which one of the most common genetic events is aberrant
p53 expression.
Recently, it has been reported that mutations in the p53
gene can also reveal an increased susceptibility to cancer
owing to inheritance ofp53 germline mutations, as frequently
occurs in the cancer-prone individuals with Li-Fraumeni
syndrome (Harris, 1993). We demonstrate here that an
inherited cancer predisposition expressed by mutagen sen-
sitivity correlates with aberrant p53 gene expression. Thus,
differences in such genetic susceptibility and in p53 expres-
sion in carcinogen-exposed epithelia of the upper aerodiges-
tive tract might have a major impact in head and neck cancer
risk assessment.
Furthermore, we detected p53-positive cells in dysplastic
and normal mucosa adjacent to tumour cells in five patients
with multiple malignancies. Our data and the identification
of p53 overexpression in premalignant lesions of the
aerodigestive tract by others (Dolcetti et al., 1992; Wang et
al., 1993; Shin et al., 1994) suggest that p53 aberrations are
an early event in the development of cancers of the upper
aerodigestive tract. Thus, according to the field cancerisation
theory, prolonged exposure to environmental carcinogens
may induce, in different areas, somatically acquired, p53 gene
mutations in normal cells with a high risk of developing
multiple cancer lesions, particularly in genetically predisposed
subjects.
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